Skip to results

Last updated date

Last updated date

Type (1 selected)

Type

Guidance programme (1 selected)

Guidance programme

Showing 1 to 18 of 18

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular eventsTA210
Prucalopride for the treatment of chronic constipation in womenTA211
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancerTA212
Trastuzumab for the treatment of HER2-positive metastatic gastric cancerTA208
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumoursTA209
Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumoursTA86
Denosumab for the prevention of osteoporotic fractures in postmenopausal womenTA204
Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal)TA206
Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal)TA207
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis CTA200
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitorTA195
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritisTA199
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemiaTA193
Capecitabine for the treatment of advanced gastric cancerTA191
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancerTA192
Human growth hormone (somatropin) for the treatment of growth failure in childrenTA188
Infliximab and adalimumab for the treatment of Crohn's diseaseTA187
Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromesTA47

Results per page

  1. 10
  2. 25
  3. 50
  4. All